TD Cowen Cuts TransMedics Group (NASDAQ:TMDX) Price Target to $120.00

TransMedics Group (NASDAQ:TMDX - Get Free Report) had its price objective dropped by investment analysts at TD Cowen from $175.00 to $120.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. TD Cowen's price target indicates a potential upside of 48.28% from the stock's previous close.

Several other equities research analysts also recently issued reports on the company. Stephens raised their price target on TransMedics Group from $151.00 to $178.00 and gave the company an "overweight" rating in a research report on Friday, August 2nd. Piper Sandler reaffirmed an "overweight" rating and issued a $180.00 target price on shares of TransMedics Group in a report on Tuesday, October 29th. Baird R W raised TransMedics Group to a "strong-buy" rating in a research report on Tuesday, September 24th. JPMorgan Chase & Co. lowered their price objective on shares of TransMedics Group from $173.00 to $116.00 and set an "overweight" rating on the stock in a research note on Tuesday, October 29th. Finally, Oppenheimer cut their target price on shares of TransMedics Group from $200.00 to $125.00 and set an "outperform" rating for the company in a research note on Tuesday, October 29th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $139.30.

TransMedics Group Stock Performance

Shares of TMDX stock traded up $0.45 during trading on Monday, reaching $80.93. The company had a trading volume of 1,825,815 shares, compared to its average volume of 973,500. The firm's 50 day simple moving average is $125.63 and its two-hundred day simple moving average is $139.55. TransMedics Group has a one year low of $66.76 and a one year high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company has a market capitalization of $2.72 billion, a PE ratio of 85.88 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. During the same period in the prior year, the business earned ($0.12) EPS. The company's revenue for the quarter was up 63.7% compared to the same quarter last year. Sell-side analysts forecast that TransMedics Group will post 1.07 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, insider Nicholas Corcoran sold 10,000 shares of the business's stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the completion of the sale, the insider now directly owns 21,105 shares of the company's stock, valued at approximately $3,714,902.10. The trade was a 32.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of the company's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the transaction, the chief executive officer now owns 61,643 shares in the company, valued at approximately $9,457,269.06. The trade was a 12.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 36,958 shares of company stock worth $5,230,528. 7.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On TransMedics Group

A number of institutional investors and hedge funds have recently modified their holdings of TMDX. Amalgamated Bank boosted its holdings in TransMedics Group by 6.7% during the second quarter. Amalgamated Bank now owns 1,114 shares of the company's stock worth $168,000 after buying an additional 70 shares during the last quarter. Pitcairn Co. raised its position in shares of TransMedics Group by 1.5% during the first quarter. Pitcairn Co. now owns 5,378 shares of the company's stock worth $398,000 after purchasing an additional 78 shares during the period. Harbour Capital Advisors LLC lifted its holdings in shares of TransMedics Group by 1.7% during the 3rd quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company's stock valued at $760,000 after purchasing an additional 81 shares in the last quarter. Signaturefd LLC grew its position in shares of TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company's stock valued at $67,000 after purchasing an additional 93 shares during the period. Finally, Arizona State Retirement System increased its stake in TransMedics Group by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 9,158 shares of the company's stock worth $1,379,000 after purchasing an additional 186 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.